626 related articles for article (PubMed ID: 18064313)
1. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
[TBL] [Abstract][Full Text] [Related]
2. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
3. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
4. Regulation of platelet heparanase during inflammation: role of pH and proteinases.
Ihrcke NS; Parker W; Reissner KJ; Platt JL
J Cell Physiol; 1998 Jun; 175(3):255-67. PubMed ID: 9572470
[TBL] [Abstract][Full Text] [Related]
5. Heparanase coagulation and cancer progression.
Nadir Y; Brenner B
Best Pract Res Clin Haematol; 2009 Mar; 22(1):85-92. PubMed ID: 19285275
[TBL] [Abstract][Full Text] [Related]
6. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
7. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
[TBL] [Abstract][Full Text] [Related]
8. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
Chan AK; Berry LR; Monagle PT; Andrew M
Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
[TBL] [Abstract][Full Text] [Related]
9. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.
Nadir Y; Brenner B; Gingis-Velitski S; Levy-Adam F; Ilan N; Zcharia E; Nadir E; Vlodavsky I
Thromb Haemost; 2008 Jan; 99(1):133-41. PubMed ID: 18217145
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
[TBL] [Abstract][Full Text] [Related]
11. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
Wang ZM; Li L; Li B; Guo SY
Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
[TBL] [Abstract][Full Text] [Related]
13. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
15. Degradation of basement membrane by prostate tumor heparanase.
Kosir MA; Wang W; Zukowski KL; Tromp G; Barber J
J Surg Res; 1999 Jan; 81(1):42-7. PubMed ID: 9889056
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
17. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
18. Heparanase multiple effects in cancer.
Nadir Y; Brenner B
Thromb Res; 2014 May; 133 Suppl 2():S90-4. PubMed ID: 24862152
[TBL] [Abstract][Full Text] [Related]
19. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
Ilan N; Elkin M; Vlodavsky I
Int J Biochem Cell Biol; 2006; 38(12):2018-39. PubMed ID: 16901744
[TBL] [Abstract][Full Text] [Related]
20. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
